Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

TRITON MINERALS LTD

ABN

99 126 042 215

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1 +Class of +securities issued or to be issued Performance rights

2 Number of *securities issued or to be issued (if known) or maximum number which may be issued 12,000,000 performance rights

Principal terms of the 3 +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities. the conversion price and dates for conversion)

Performance rights are issued to the Managing Director in accordance with the terms and conditions approved by shareholders at the annual general meeting held 2 December 2016. On vesting, one Performance Right is converted into one fully paid ordinary share in the Company. Vesting is subject to vesting conditions set out in the Notice of General Meeting held 2 December 2016.

4	 Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities? If the additional *securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or 	No – not quoted
	dividend, distribution or interest payment	
5	Issue price or consideration	Nil cash consideration
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Performance rights are issued as a cost effective way to remunerate the Managing Director, as opposed to cash remuneration and is reasonable, given the vesting conditions will align the interests of the Managing Director with those of shareholders.
62	Is the entity on teligible entity	Vac
6a	Is the entity an ⁺ eligible entity that has obtained security holder approval under rule 7.1A?	Yes
	If Yes, complete sections 6b – 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	2 December 2016
6с	Number of <i>*</i> securities issued without security holder approval under rule 7.1	Nil
6d	Number of *securities issued with security holder approval under rule 7.1A	Nil

⁺ See chapter 19 for defined terms.

- 6e Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)
- 6f Number of +securities issued under an exception in rule 7.2
- 6g If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.
- 6h If ⁺securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements
- 6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements
- 7 ⁺Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

8 Number and ⁺class of all ⁺securities quoted on ASX (*including* the ⁺securities in section 2 if applicable and including securities suspended or the subject of application for quotation)

12,000,000	performance	rights
------------	-------------	--------

N/A

N/A

Capacity under 7.1 is 98,670,695 Capacity under 7.1A is 65,780,463

9 December 2016

Number	+Class
657,804,633 (TON)	Ordinary Fully Paid
22,220,506 (TONOA)	Listed options exercisable at \$0.15, expiry 16 March 2017

		Number	+Class
9	Number and ⁺ class of all	Inumber	Class
9	*securities not quoted on ASX (<i>including</i> the *securities in section 2 if applicable)	7,918,957	Unlisted Option, Expiry Date 31 December 2016, Ex \$0.10
		5,000,000	Unlisted Option, Expiry Date 23 July 2017, Ex \$1.00
		5,000,000	Unlisted Option, Expiry Date 25 August 2017, Ex \$0.70
		4,548,763	Unlisted Option, Expiry Date 23 January 2018, Ex \$0.2748
		696,426	Unlisted Option, Expiry Date 16 March 2017, Ex \$0.20
		50,000,000	Unlisted Option, Expiry Date 30 June 2018, Ex \$0.10
		4,500,000	Performance rights, expiry 20 August 2018, conversion subject to vesting conditions.
		6,000,000	Performance rights, expiry 2 March 2019, conversion subject to vesting conditions.
		6,000,000	Performance rights, expiry 2 December 2019, conversion subject to vesting conditions.
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	N/A	

⁺ See chapter 19 for defined terms.

Part 2 - Pro rata issue – Not applicable

11	Is security holder approval required?
12	Is the issue renounceable or non- renounceable?
13	Ratio in which the ⁺ securities will be offered
14	⁺ Class of ⁺ securities to which the offer relates
15	⁺ Record date to determine entitlements
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?
17	Policy for deciding entitlements in relation to fractions
18	Names of countries in which the entity has security holders who will not be sent new offer documents
	Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.
19	Closing date for receipt of acceptances or renunciations
20	Names of any underwriters
21	Amount of any underwriting fee or commission
22	Names of any brokers to the issue
23	Fee or commission payable to the broker to the issue

- 24 Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders
- 25 If the issue is contingent on security holders' approval, the date of the meeting
- 26 Date entitlement and acceptance form and offer documents will be sent to persons entitled
- 27 If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders
- 28 Date rights trading will begin (if applicable)
- 29 Date rights trading will end (if applicable)
- 30 How do security holders sell their entitlements *in full* through a broker?
- 31 How do security holders sell *part* of their entitlements through a broker and accept for the balance?
- 32 How do security holders dispose of their entitlements (except by sale through a broker)?
- 33 ⁺Issue date

.

+ See chapter 19 for defined terms.



Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34	Type of ⁺ securities (<i>tick one</i>)
(a)	+Securities described in Part 1)
(b)	All other ⁺ securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35		If the ⁺ securities are ⁺ equity securities, the names of the 20 largest holders of the additional ⁺ securities, and the number and percentage of additional ⁺ securities held by those holders
36		If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over
37		A copy of any trust deed for the additional ⁺ securities
Entit	ies tha	t have ticked box 34(b)

38	Number of *securities for which *quotation is sought	N/A
39	⁺ Class of ⁺ securities for which quotation is sought	N/A

40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	N/A	
	 If the additional *securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 		
41	Reason for request for quotation now	N/A	
	Example: In the case of restricted securities, end of restriction period		
	(if issued upon conversion of another ⁺ security, clearly identify that other ⁺ security)		
		Number	+Class
42	Number and ⁺ class of all ⁺ securities quoted on ASX (<i>including</i> the ⁺ securities in clause 38)	N/A	

⁺ See chapter 19 for defined terms.

Quotation agreement

- ¹ ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those **securities* should not be granted **quotation*.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the ⁺securities to be quoted under section 1019B of the Corporations Act at the time that we request that the ⁺securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before ⁺quotation of the ⁺securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

== == == == ==

..... (Company secretary)

Sign here:

Date: 9 December 2016

Print name:

Paige Exley

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital				
Step 1: Calculate "A", the base figure from which the placement capacity is calculated				
<i>Insert</i> number of fully paid ⁺ ordinary securities on issue 12 months before the ⁺ issue date or date of agreement to issue	376,549,422			
Add the following:				
 Number of fully paid ⁺ordinary securities issued in that 12 month period under an exception in rule 7.2 	176,006,811			
 Number of fully paid ⁺ordinary securities issued in that 12 month period with shareholder approval 	105,248,400			
 Number of partly paid ⁺ordinary securities that became fully paid in that 12 month period 				
 Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 				
Subtract the number of fully paid ⁺ ordinary securities cancelled during that 12 month period	0			
" A "	657,804,633			

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"	Step 2: Calculate 15% of "A"			
"B"	0.15			
	[Note: this value cannot be changed]			
<i>Multiply</i> "A" by 0.15	98,670,695			
Step 3: Calculate "C", the amount of 7.1 that has already been used	of placement capacity under rule			
<i>Insert</i> number of ⁺ equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	Nil			
Under an exception in rule 7.2				
Under rule 7.1A				
• With security holder approval under rule 7.1 or rule 7.4				
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 				
"C"	Nil			
Step 4: Subtract "C" from ["A" x "E placement capacity under rule 7.1	3"] to calculate remaining			
"A" x 0.15	98,670,695			
Note: number must be same as shown in Step 2				
Subtract "C"	Nil			
Note: number must be same as shown in Step 3				
<i>Total</i> ["A" x 0.15] – "C"	98,670,695			
	[Note: this is the remaining placement capacity under rule 7.1]			

⁺ See chapter 19 for defined terms.

Part 2 – Not Applicable

Rule 7.1A – Additional placement capacity for eligible entities Step 1: Calculate "A", the base figure from which the placement capacity is calculated	
Note: number must be same as shown in Step 1 of Part 1	
Step 2: Calculate 10% of "A"	
"D"	0.10
	Note: this value cannot be changed
<i>Multiply</i> "A" by 0.10	65,780,463
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used	
<i>Insert</i> number of ⁺ equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	Nil
 Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items 	
"E"	Nil

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A

, , ,	
"A" x 0.10	65,780,463
Note: number must be same as shown in Step 2	
Subtract "E"	Nil
Note: number must be same as shown in Step 3	
<i>Total</i> ["A" x 0.10] – "E"	65,780,463
	Note: this is the remaining placement capacity under rule 7.1A

⁺ See chapter 19 for defined terms.